ArticleScience and technology of advanced materials2026
Spatial control of PEG-lipid interfaces at cell surface enables on-demand adhesion and enzymatic detachment of suspension cells.
Article in Science and technology of advanced materials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Suspension cells are widely used in biomedical research and cell-based therapies; however, their lack of stable adhesion to substrates limits their efficient handling, including gene delivery and downstream processing. Although surface engineering approaches have been studied to induce cell adhesion, precise control over attachment and detachment, comparable to that of adherent cells, remains challenging. Here, we report a strategy to control cell adhesion and detachment using enzyme-responsive trans-activator of transcription peptide-poly(ethylene glycol)-lipid (Tat-PEG-lipid) conjugates and non-functional poly(ethylene glycol)-lipids (PEG-lipid). A collagenase-cleavable peptide sequence was inserted between the Tat peptide and the PEG chain, yielding Tat-Col-PEG-lipid constructs with PEG molecular weights of 20 and 40 kDa. These conjugates were incorporated into the cell membranes of CCRF-CEM cells, a human T-lymphoblastoid cell line, to induce adhesion via the Tat peptide. To regulate the interfacial structure, Tat-Col-PEG-lipid was co-assembled with a non-functional PEG(5k)-lipid, enabling precise control over the surface density to improve collagenase access. We demonstrated that the mixed PEG-lipid modification allows robust cell adhesion to substrates while enabling efficient detachment upon collagenase treatment. Notably, the use of Tat-Col-PEG-lipids with longer PEG chains (40 kDa) significantly improved the adhesion efficiency, enzymatic detachment, and cell viability compared to shorter PEG chains. Optimal mixing ratios of Tat-Col-PEG(40k)-lipids and PEG(5k)-lipids resulted in stable attachment and rapid collagenase-triggered release across different substrates, planar surfaces, and fibrous scaffolds. This hierarchical PEG-lipid modification approach provides a versatile and minimally invasive platform for the transient manipulation of suspended cells, with potential applications in gene delivery, cell processing, and regenerative medicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.